PSTV Stock Overview
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Plus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.98 |
| 52 Week High | US$7.20 |
| 52 Week Low | US$0.97 |
| Beta | 0.45 |
| 1 Month Change | 23.75% |
| 3 Month Change | -27.47% |
| 1 Year Change | -66.15% |
| 3 Year Change | -93.53% |
| 5 Year Change | -99.18% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating
Oct 07Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end
Sep 22Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02
Jul 21Plus Therapeutics CEO Dr. Marc Hedrick - Cancer's Hardest Problems
Dec 21Does Plus Therapeutics (NASDAQ:PSTV) Have A Healthy Balance Sheet?
Aug 25
Plus Therapeutics to proceed with eighth cohort in ReSPECT glioblastoma trial
Jun 16Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why
May 11Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract
May 04Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?
Feb 23Plus Therapeutics shows positive data for ReSPECT Phase 1 clinical trial in GBM
Nov 19Shareholder Returns
| PSTV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 15.1% | 3.8% | 0.9% |
| 1Y | -66.2% | -5.8% | 13.6% |
Return vs Industry: PSTV underperformed the US Biotechs industry which returned -7.8% over the past year.
Return vs Market: PSTV underperformed the US Market which returned 11.7% over the past year.
Price Volatility
| PSTV volatility | |
|---|---|
| PSTV Average Weekly Movement | 23.0% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PSTV is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.
Volatility Over Time: PSTV's weekly volatility has increased from 16% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 17 | Marc Hedrick | https://plustherapeutics.com |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection.
Plus Therapeutics, Inc. Fundamentals Summary
| PSTV fundamental statistics | |
|---|---|
| Market Cap | US$8.14m |
| Earnings (TTM) | -US$15.16m |
| Revenue (TTM) | US$3.75m |
2.4x
P/S Ratio-0.6x
P/E RatioIs PSTV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSTV income statement (TTM) | |
|---|---|
| Revenue | US$3.75m |
| Cost of Revenue | US$9.03m |
| Gross Profit | -US$5.28m |
| Other Expenses | US$9.88m |
| Earnings | -US$15.16m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.35 |
| Gross Margin | -140.84% |
| Net Profit Margin | -404.27% |
| Debt/Equity Ratio | 165.8% |
How did PSTV perform over the long term?
See historical performance and comparison